$15 million supports quest for personalized leukemia therapies

$15 million supports quest for personalized leukemia therapies

Investigators at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have been awarded a $15 million grant to better understand the genetic changes that drive acute myeloid leukemia (AML), a deadly blood cancer, and predict patients’ responses to therapy. The findings also may enable investigators to develop more effective therapies tailored to patients, based on the genetic characteristics of their cancer cells.
Genes linked to Alzheimer’s risk, resilience ID’d

Genes linked to Alzheimer’s risk, resilience ID’d

A team led by researchers at the School of Medicine in St. Louis has identified a pair of genes that influence risk for Alzheimer’s disease. The genes — known as MS4A4A and TREM2 — affect the brain’s immune cells. They influence Alzheimer’s risk by altering levels of TREM2, a protein that is believed to help microglia cells clear excessive amounts of the Alzheimer’s proteins amyloid and tau from the brain.
Rethinking seizures associated with cardiac disease

Rethinking seizures associated with cardiac disease

Research from Washington University in St. Louis finds that mutations of a gene implicated in long QT syndrome in humans may trigger seizures because of their direct effects on certain classes of neurons in the brain — independent from what the genetic mutations do to heart function. The new work from Arts & Sciences was conducted with fruit flies and is published August 8 in PLOS Genetics.
Older Stories